<DOC>
	<DOCNO>NCT00399035</DOCNO>
	<brief_summary>The purpose study determine Cediranib add chemotherapy effective chemotherapy alone prolong life expectancy slow disease progression patient previously untreated metastatic colorectal cancer .</brief_summary>
	<brief_title>Cediranib ( AZD2171 , RECENTINâ„¢ ) Addition Chemotherapy Patients With Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Written Informed Consent Carcinoma colon rectum One measurable lesion Adjuvant/neoadjuvant therapy within 612 month study entry Untreated unstable brain meningeal metastasis Specific laboratory range Specific cardiovascular problem Participation trial within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Cediranib</keyword>
	<keyword>RECENTIN</keyword>
</DOC>